Studies suggest that vitamin D deficiency is a risk factor for cardiovascular disease and diabetes. Vitamin D deficiency is prevalent in HIV patients but the effect of vitamin D supplementation on cardiovascular risk in this population is unknown.
Methods
We conducted a randomized, double-blind, placebo-controlled trial among 45 HIV-infected adults in Cleveland (OH, USA) on stable antiretroviral therapy with durable virological suppression and a baseline serum 25-hydroxyvitamin D level of ≤20 ng/ml. Participants were randomized 2:1 to vitamin D3 4,000 IU daily or placebo for 12 weeks. The primary outcome was a change in flow-mediated brachial artery dilation (FMD).
Results
Baseline demographics were similar except for age (vitamin D versus placebo, mean ±sd 47 ±8 versus 40 ±10 years; P=0.009). Both groups had reduced FMD at baseline (median values 2.9% [IQR 1.6–4.8] for vitamin D versus 2.5% [IQR 1.7–6.4] for placebo; P=0.819). Despite an increase in the concentration of serum 25-hydroxyvitamin D from baseline to 12 weeks (5.0 ng/ ml [IQR -0.9–7.4] versus -1.9 ng/ml [IQR -4.0–0.1] for vitamin D versus placebo, respectively; P=0.003), there was no difference in FMD change (0.55% [IQR -1.05– 2.13] versus 0.29% [IQR -1.61–1.77]; P=0.748). Vitamin D supplementation was associated with a decrease in total and non-high-density lipoprotein cholesterol, and an increase in indices of insulin resistance.
Conclusions
Among HIV-infected individuals with vitamin D deficiency, supplementation with 4,000 IU vitamin D3 daily for 12 weeks modestly improved vitamin D status and cholesterol but worsened insulin resistance without change in endothelial function. The mechanisms of resistance to standard doses of vitamin D and the complex role of vitamin D in glucose metabolism in this population require further investigation.
References
1.
HolickM.F.Vitamin D deficiency. N Engl J Med2007; 357: 266–281.
2.
LeeJ.H., O'KeefeJ.H., BellD., HensrudD.D., HolickM.F.Vitamin D deficiency an important, common, and easily treatable cardiovascular risk factor?J Am Coll Cardiol2008; 52: 1949–1956.
3.
JuddS.E., NanesM.S., ZieglerT.R., WilsonP.W., TangprichaV.Optimal vitamin D status attenuates the age-associated increase in systolic blood pressure in white Americans: results from the third National Health and Nutrition Examination Survey. Am J Clin Nutr2008; 87: 136–141.
4.
WangT.J., PencinaM.J., BoothS.L.Vitamin D deficiency and risk of cardiovascular disease. Circulation2008; 117: 503–511.
5.
GiovannucciE., LiuY., HollisB.W., RimmE.B.25-hydroxyvitamin D and risk of myocardial infarction in men: a prospective study. Arch Intern Med2008; 168: 1174–1180.
6.
DobnigH., PilzS., ScharnaglH.Independent association of low serum 25-hydroxyvitamin D and 1,25-dihydroxyvitamin D levels with all-cause and cardiovascular mortality. Arch Intern Med2008; 168: 1340–1349.
7.
AutierP., GandiniS.Vitamin D supplementation and total mortality: a meta-analysis of randomized controlled trials. Arch Intern Med2007; 167: 1730–1737.
8.
RossA.C., MansonJ.E., AbramsS.A.The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. J Clin Endocrinol Metab2011; 96: 53–58.
9.
DeanfieldJ.E., HalcoxJ.P., RabelinkT.J.Endothelial function and dysfunction: testing and clinical relevance. Circulation2007; 115: 1285–1295.
10.
SugdenJ.A., DaviesJ.I., WithamM.D., MorrisA.D., StruthersA.D.Vitamin D improves endothelial function in patients with Type 2 diabetes mellitus and low vitamin D levels. Diabet Med2008; 25: 320–325.
11.
TarcinO., YavuzD.G., OzbenB.Effect of vitamin D deficiency and replacement on endothelial function in asymptomatic subjects. J Clin Endocrinol Metab2009; 94: 4023–4030.
12.
WithamM.D., DoveF.J., DryburghM., SugdenJ.A., MorrisA.D., StruthersA.D.The effect of different doses of vitamin D(3) on markers of vascular health in patients with type 2 diabetes: a randomised controlled trial. Diabetologia2010; 53: 2112–2119.
13.
JablonskiK.L., ChoncholM., PierceG.L., WalkerA.E., SealsD.R.25-Hydroxyvitamin D deficiency is associated with inflammation-linked vascular endothelial dysfunction in middle-aged and older adults. Hypertension2011; 57: 63–69.
OvertonE.T., YinM.T.The Rapidly Evolving Research on Vitamin D Among HIV-Infected Populations. Curr Infect Dis Rep2011; 13: 83–93.
16.
MehtaS., GiovannucciE., MugusiF.M.Vitamin D status of HIV-infected women and its association with HIV disease progression, anemia, and mortality. PLoS ONE2010; 5: e8770.
17.
SzepZ., GuaraldiG., ShahS.S.Vitamin D deficiency is associated with type 2 diabetes mellitus in HIV infection. AIDS2011; 25: 525–529.
18.
RossA.C., JuddS., KumariM.Vitamin D is linked to carotid intima-media thickness and immune reconstitution in HIV-positive individuals. Antivir Ther2011; 16: 555–563.
19.
ChoiA.I., LoJ.C., MulliganK.Association of vitamin D insufficiency with carotid intima-media thickness in HIV-infected persons. Clin Infect Dis2011; 52: 941–944.
20.
ArpadiS.M., McMahonD., AbramsE.J.Effect of bimonthly supplementation with oral cholecalciferol on serum 25-hydroxyvitamin D concentrations in HIV-infected children and adolescents. Pediatrics2009; 123: e121–e126.
21.
HolickM.F., BinkleyN.C., Bischoff-FerrariH.A.Evaluation, treatment, and prevention of vitamin d deficiency: an endocrine society clinical practice guideline. J Clin Endocrinol Metab2011; 96: 1911–1930.
22.
DaoC.N., PatelP., OvertonE.T.Low vitamin D among HIV-infected adults: prevalence of and risk factors for low vitamin D levels in a cohort of HIV-infected adults and comparison to prevalence among adults in the US general population. Clin Infect Dis2011; 52: 396–405.
23.
WelzT., ChildsK., IbrahimF.Efavirenz is associated with severe vitamin D deficiency and increased alkaline phosphatase. AIDS2010; 24: 1923–1928.
24.
BrownT.T., McComseyG.A.Association between initiation of antiretroviral therapy with efavirenz and decreases in 25-hydroxyvitamin D. Antivir Ther2010; 15: 425–429.
25.
WohlD.A., DoroanaO., PilottoJ.Change in vitamin D levels smaller and risk of development of severe vitamin D deficiency lower among HIV-1-infected, treatment-naive adults receiving TMC278 compared with EFV: 48-week results from the phase III ECHO trial.18th Conference on Retroviruses and Opportunistic Infections. 27 February–2 March 2011, Boston, MA, USA. Abstract 79LB.
26.
FoxJ., PetersB., PrakashM., ArribasJ., HillA., MoecklinghoffC.Improvement in vitamin D deficiency following antiretroviral regime change: results from the MONET Trial. AIDS Res Hum Retroviruses2010; 26: 1–4.
27.
MatthewsD.R., HoskerJ.P., RudenskiA.S., NaylorB.A., TreacherD.F., TurnerR.C.Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia1985; 28: 412–419.
28.
TorrianiF.J., KomarowL., ParkerR.A.Endothelial function in human immunodeficiency virus-infected antiretroviral-naive subjects before and after starting potent antiretroviral therapy: The ACTG (AIDS Clinical Trials Group) Study 5152s. J Am Coll Cardiol2008; 52: 569–576.
29.
CorrettiM.C., AndersonT.J., BenjaminE.J.Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol2002; 39: 257–265.
30.
OvertonE.T., GrubbJ., BakerJ.Prevalence and risk factors for insulin resistance in the study to understand the natural history of HIV (SUN study) cohort.6th IAS Conference on HIV Pathogenesis, Treatment and Prevention. 17–20 July 2011, Rome, Italy. Abstract TUPE13L.
31.
SolagesA., VitaJ.A., ThorntonD.J.Endothelial function in HIV-infected persons. Clin Infect Dis2006; 42: 1325–1332.
32.
HilemanC.O., CarmanT.L., GripshoverB.M.Salsalate is poorly tolerated and fails to improve endothelial function in virologically suppressed HIV-infected adults. AIDS2010; 24: 1958–1961.
33.
WitteD.R., WesterinkJ., de KoningE.J., van der GraafY., GrobbeeD.E., BotsM.L.Is the association between flow-mediated dilation and cardiovascular risk limited to low-risk populations?J Am Coll Cardiol2005; 45: 1987–1993.
34.
HeaneyR.P., DaviesK.M., ChenT.C., HolickM.F., Barger-LuxM.J.Human serum 25-hydroxycholecalciferol response to extended oral dosing with cholecalciferol. Am J Clin Nutr2003; 77: 204–210.
35.
van den Bout-van den BeukelC.J., van den BosM., OyenW.J.The effect of cholecalciferol supplementation on vitamin D levels and insulin sensitivity is dose related in vitamin D-deficient HIV-1-infected patients. HIV Med2008; 9: 771–779.
36.
PascussiJ.M., RobertA., NguyenM.Possible involvement of pregnane X receptor-enhanced CYP24 expression in drug-induced osteomalacia. J Clin Invest2005; 115: 177–186.
37.
MitriJ., MuraruM.D., PittasA.G.Vitamin D and type 2 diabetes: a systematic review. Eur J Clin Nutr2011; 65: 1005–1015.
38.
WithamM.D., NadirM.A., StruthersA.D.Effect of vitamin D on blood pressure: a systematic review and meta-analysis. J Hypertens2009; 27: 1948–1954.
39.
SchwartzJ.B.Effects of vitamin D supplementation in atorvastatin-treated patients: a new drug interaction with an unexpected consequence. Clin Pharmacol Ther2009; 85: 198–203.
40.
Gannagé-YaredM.H., ChedidR., KhalifeS., AzziE., ZoghbiF., HalabyG.Vitamin D in relation to metabolic risk factors, insulin sensitivity and adiponectin in a young Middle-Eastern population. Eur J Endocrinol2009; 160: 965–971.
41.
RossA.C., ArmentroutR., O'RiordanM.A.Endothelial activation markers are linked to HIV status and are independent of antiretroviral therapy and lipoatrophy. J Acquir Immune Defic Syndr2008; 49: 499–506.
42.
BrownT.T., TassiopoulosK., BoschR.J., ShikumaC., McComseyG.A.Association between systemic inflammation and incident diabetes in HIV-infected patients after initiation of antiretroviral therapy. Diabetes Care2010; 33: 2244–2249.
43.
PetersonC.A., HeffernanM.E.Serum tumor necrosis factor-alpha concentrations are negatively correlated with serum 25(OH)D concentrations in healthy women. J Inflamm (Lond)2008; 5: 10.
